15/02/2024
Deep Pharma Intelligence is pleased to have its Pharma AI industry analytics research featured in a recent article in Forbes, ‘A New Era Of Drug Discovery With Biology-Driven AI’, written by Forbes Council Member, author and President & CEO of BPGbio Inc., Niven R Narain, Ph.D.
“As we saw at the January 2024 J.P. Morgan Healthcare Conference, a key event in the healthcare industry, one of the most prominent topics of discussion was the use of AI to accelerate health innovation. Deep Pharma Intelligence reports a 27-fold increase in the amount of capital invested in AI-driven pharma companies since 2015, with the leading 800 such companies receiving $59.3 billion in funding as of December 2022.”
The article underscores a remarkable era where AI's integration into drug discovery heralds better, faster, and more cost-effective advancements. DPI's contributions are highlighted through our analytics, revealing a 27-fold increase in capital investment in AI-driven pharma companies since 2015. This surge underscores a burgeoning confidence in AI's potential to expedite and enhance drug discovery, with leading companies receiving substantial funding to pioneer new therapies.
Narain's insightful analysis extends beyond the biotech sector, illustrating how traditional pharmaceutical giants and emerging AI startups collaborate to harness AI's power. This synergy aims to accelerate the journey from concept to clinical trials, promising a future where medical breakthroughs are both rapid and financially viable.
The narrative of AI in pharma is evolving, moving from an era of heightened expectations to one of practical, biology-first approaches that yield real-world benefits. Narain's call to action emphasizes AI's role as an invaluable tool in drug discovery, not a standalone solution. By integrating AI with deep biological insights, the industry stands on the cusp of delivering targeted, effective treatments to patients faster than ever before.
As we navigate this exciting landscape, DPI remains at the forefront, providing cutting-edge analytics and insights that drive the pharma industry forward.
Read the full Forbes article here: https://www.forbes.com/sites/forbestechcouncil/2024/02/14/a-new-era-of-drug-discovery-with-biology-driven-ai/?sh=5dab0a427fc0
And keep up to date with Deep Pharma Intelligence news, open-source analytics and commercial products and services here: https://www.deep-pharma.tech/products
The AI and computing revolution is ushering in a new era of drug development that is poised to be better, faster and cheaper.
